News from Target Ovarian Cancer

Latest news stories

The news contained in this area falls into a number of categories.  You can select the type of news you wish to see using the scroll down bar.  Leaving the selection blank will mean you see all the news, with the most recent item first. News is archived according to date.

Categories include

  • Target Ovarian Cancer
  • Fundraising
  • Research
  • In the media
Microscope sml

14.06.13 In the news: Yesterday the US Supreme Court ruled that human genes may not be patented. Target Ovarian Cancer welcomes important legal breakthrough in the United States surrounding testing for familial breast and ovarian cancer

Nightrider TOC team

10.06.13 Bumper weekend of fundraising activity raises over £22,000 Target Ovarian Cancer's teams in both the Nightrider weekend and Broadgate Tower abseil have raised an incredible £22,000 for the charity.

Portcullis Green 250

06.06.13 The inequity of access to Avastin discussed at the All Party Parliamentary Group on Ovarian Cancer MPs heard yesterday about fears over the future funding of Avastin in England, and the challenges facing women around the UK in terms of accessing the drug, given recent negative decisions by both the National Institute of Health and Care Excellence (NICE) and the Scottish Medicines Consortium...

ASCO logo

03.06.13 In the news: Votrient (pazopanib) improves progression-free survival in Phase III trial of women with ovarian cancer. Data presented at the 2013 Annual Meeting of the American Society of Clinical Oncology this weekend shows that the drug Votrient (pazopanib), developed by GlaxoSmithKine, improves progression-free survival for women with ovarian cancer by an average of almost six months.

News archive

Latest stories

2013
2012
2011
2010
2009
2008
Register to receive our regular newsletter.

Newsletter

Site by NEMISYS

Trustees Joanna Barker D.Litt (Chairman), Lisa Attenborough, Sylvia Auton, Sonya Branch, Mike Holt (Hon Treasurer), Kate Kirkland and Helen MacNamara

Patrons Professor Sir Kenneth Calman PhD MD FRCS FRCP, Dame Janet Gaymer DBE QC

Chief Executive Annwen Jones

Target Ovarian Cancer is a company limited by guarantee, registered in England and Wales (No. 6619981).
Registered office: 30 Angel Gate, London EC1V 2PT. Registered charity numbers 1125038 (England and Wales) and SC042920 (Scotland).